Quality medications help save lives: Reducing the risks from substandard and falsified COVID-19 treatments

The supply and demand imbalances caused by the COVID-19 pandemic has created a surge in substandard and falsified treatments. USP is working with public health organizations, pharmacopeias, manufacturers and regulators in the U.S. and around the world to combat poor-quality medicines and build the public’s trust in COVID-19 treatments. Our resources and tools help ensure the quality of medical products for drug ingredients and finished products. USP is committed to strengthening the supply of trusted, quality medicines needed to fight the pandemic.

substandard and falsified medicines whitepaper
Protecting the supply chain of COVID-19 health products

USP responds to the surge of substandard and falsified health products triggered by the COVID-19 pandemic.

Read the white paper

remdesivir toolkit
USP Methods to Assist in Detecting Falsified Remdesivir

Newly released methods to identify substandard and falsified remdesivir can help ensure hospitalized COVID-19 patients are receiving the quality treatments they need.

See the resource